The CHI-CAT score shows greater predictive capability for cancer-associated venous thromboembolism risk compared to the Khorana score.
Does the CHI-CAT score improve the prediction of cancer-associated venous thromboembolism compared to the Khorana score in hospitalized Chinese cancer patients?
The CHI-CAT score provides a more accurate, population-specific tool for predicting venous thromboembolism risk in Chinese cancer patients compared to the standard Khorana score.
Absolute Event Rate: 0% vs 0%
The CHI-CAT score has been developed and validated, demonstrating relatively comprehensive components and a predictive capability that exceeds the Khorana score. However, its reliability and validation need improvement through testing in larger internal and external retrospective cohorts.
Qin et al. (Mon,) reported a other. The CHI-CAT score shows greater predictive capability for cancer-associated venous thromboembolism risk compared to the Khorana score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: